Fractyl Health, Inc. Common Stock
GUTSNASDAQHealthcare● Active
$0.67
$-0.01(-1.27%)
Market Cap$48369826
P/E Ratio—
52W High$2.9
52W Low$0.377
Fractyl Health, Inc. Common Stock (GUTS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GUTS · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.13
Est. -$0.17 · +23.5%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
GUTS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.15 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.17 | -$0.13 | +23.5% | — | — | — |
| ▲ Q1 FY2026 | Mar 24, 2026 | -$0.19 | $0.15 | +178.9% | — | — | — |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.34 | -$0.35 | -2.9% | — | — | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.37 | -$0.53 | -43.2% | — | — | — |
| — Q2 FY2025 | May 13, 2025 | -$0.49 | -$0.49 | +0.0% | — | — | — |
| ▼ Q1 FY2025 | Mar 3, 2025 | -$0.44 | -$0.52 | -18.2% | $0.00B | $0.00B | -70.0% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.50 | -$0.48 | +4.0% | $0.00B | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.15
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.13
EPS Est.
-$0.17
EPS Surpr.
+23.5%
Revenue
—
Q1 FY2026
Mar 24, 2026Beat
EPS Actual
$0.15
EPS Est.
-$0.19
EPS Surpr.
+178.9%
Revenue
—
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$0.35
EPS Est.
-$0.34
EPS Surpr.
-2.9%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.53
EPS Est.
-$0.37
EPS Surpr.
-43.2%
Revenue
—
Q2 FY2025
May 13, 2025
EPS Actual
-$0.49
EPS Est.
-$0.49
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2025
Mar 3, 2025Miss
EPS Actual
-$0.52
EPS Est.
-$0.44
EPS Surpr.
-18.2%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.48
EPS Est.
-$0.50
EPS Surpr.
+4.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $0.06 | $0.06 | $0.06 | 1 |
| Q3 FY2030 | $0.04 | $0.04 | $0.04 | 1 |
| Q2 FY2030 | $0.05 | $0.05 | $0.05 | 1 |
| Q1 FY2030 | $0.02 | $0.02 | $0.02 | 1 |
| Q4 FY2029 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q3 FY2029 | $-0.04 | $-0.04 | $-0.04 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +23.5% | $0.77 | $0.73 | -4.55% |
| ▲ Q1 FY2026 | Mar 24, 2026 | +178.9% | $0.45 | $0.43 | -3.48% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -2.9% | $1.10 | $1.13 | +2.73% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -43.2% | $0.98 | $0.98 | +0.71% |
| ▲ Q2 FY2025 | May 13, 2025 | +0.0% | $1.71 | $1.77 | +3.51% |
| ▼ Q1 FY2025 | Mar 3, 2025 | -18.2% | $1.56 | $1.56 | +0.00% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +4.0% | $2.51 | $2.43 | -3.19% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +21.7% | $2.30 | $2.23 | -3.04% |
Q2 FY2026-4.55%
Report Date
May 12, 2026
EPS Beat/Miss
+23.5%
Price Before
$0.77
Price After
$0.73
Q1 FY2026-3.48%
Report Date
Mar 24, 2026
EPS Beat/Miss
+178.9%
Price Before
$0.45
Price After
$0.43
Q4 FY2025+2.73%
Report Date
Nov 12, 2025
EPS Beat/Miss
-2.9%
Price Before
$1.10
Price After
$1.13
Q3 FY2025+0.71%
Report Date
Aug 12, 2025
EPS Beat/Miss
-43.2%
Price Before
$0.98
Price After
$0.98
Q2 FY2025+3.51%
Report Date
May 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.71
Price After
$1.77
Q1 FY2025+0.00%
Report Date
Mar 3, 2025
EPS Beat/Miss
-18.2%
Price Before
$1.56
Price After
$1.56
Q4 FY2024-3.19%
Report Date
Nov 12, 2024
EPS Beat/Miss
+4.0%
Price Before
$2.51
Price After
$2.43
Q3 FY2024-3.04%
Report Date
Aug 14, 2024
EPS Beat/Miss
+21.7%
Price Before
$2.30
Price After
$2.23
Avg Beat Reaction-2.15%
Avg Miss Reaction+1.15%
Beat Rate5 / 8 quarters
Largest Move-4.55% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GUTS ends December
Fractyl Health, Inc. Common Stock (GUTS) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.13 — beating the analyst consensus of $-0.17 by +23.5%. GUTS has beaten EPS estimates for 2 consecutive quarters. The next GUTS earnings date is expected around September 1, 2026.
Each quarter, investors track GUTS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GUTS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GUTS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GUTS earnings · 5 questionsFractyl Health, Inc. Common Stock's next earnings report is expected around September 1, 2026. GUTS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GUTS historically reports after market close (AMC).
GUTS earnings datewhen is GUTS earningsGUTS next earnings datewhen does GUTS report earningsGUTS earnings calendar
▸ Source: FMP · Fractyl Health, Inc. Common Stock SEC filings · US GAAP · Fractyl Health, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026